Search

Psycho-oncology and psycho-neuro-immunology are both powerful new disciplines. Although a lot of literature exists in both of these fields the evidence is often controversial. This paper gives a brief perspective on the origins of psychoneuro- immunology and discusses how our current understanding of this subject can be translated into clinical practice in an Indian setting. [ABSTRACT FROM AUTHOR]

The article reports developments related to attention deficit hyperactivity disorder(ADHD) medication in the U.S. The new drug application of Shire's ADHD is undergoing a review at the Food and Drug Administration which will be completed by April 9, 2006. Alza Corp. Concerta, a delayed release stimulant used to treat attention deficit hyperactivity disorder has been found to be less likely to be abused. The CX717 of Cortex Pharmaceuticals Inc. clinical trial has shown positive results.

The article presents news briefs related to breast cancer. The drug Herceptin, developed by Genentech Inc., have shown that it possess the potential to reduce the risk of breast cancer recurrence in woman with a particularly aggressive form of the disease. An issue of the British medical journal "The Lancet" contained an article that has produced skepticism about Genentech Inc.'s anticancer drug. Further, it includes information about Schering AG, which has acquired a license to the promising anticancer product, Tocosol paclitaxel. It also includes information on a drug combination from Introgen Therapeutics Inc. and Pfizer Inc.